Observational studyHIV medicine2025
Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics.
Observational study in HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Real-World Safety and Effectiveness of Cabotegravir in People Living with HIV: Interim Report of a Post-marketing Surveillance in Japan.Advances in therapy · 2026Article
- Clinically Relevant Risk of Hepatitis B Virus Infection and Reactivation in People With HIV After Withdrawal of Anti-HBV-Active Antiretroviral Therapy in Japan.Open forum infectious diseases · 2026Article
- Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics.HIV medicine · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLong-acting cabotegravir plus rilpivirine (CAB+RPV) offers an alternative to daily oral therapy, but real-world data in East Asia remain scarce. This study aims to evaluate the impact of CAB+RPV in people with HIV in Japan, focusing on virological outcomes, treatment continuation and inflammatory markers, providing valuable insight into the use of injectable regimens in clinical practice.
methodsThis multicentre retrospective study analysed routinely collected data from eight HIV centres in Japan on people with HIV who initiated CAB+RPV before January 2024. Virological, renal, inflammatory and lipid outcomes were assessed using follow-up laboratory data obtained through April 2025.
resultsAmong 136 participants, over 95% maintained HIV RNA <50 copies/mL, and more than 75% sustained undetectable levels through 14 months. No virological failures occurred. Seven participants (5.1%) discontinued treatment, mostly due to injection site reactions (ISRs). Serum creatinine and cystatin C significantly decreased overall, although a significant change in serum creatinine was not observed in the subgroup switching from a regimen that did not contain a renal tubular transport inhibitor. CD4 and CD8 cell counts declined (median changes: -32 cells/μL, p = 0.0047; -52 cells/μL, p < 0.0001), with no significant change in the CD4/CD8 ratio or CRP. high-density lipoprotein cholesterol (HDL-c) increased significantly (p = 0.0005), while LDL-c and the T-chol/HDL-c ratio remained unchanged.
conclusionsThis study provides the first multicentre real-world data on CAB+RPV in Japan, demonstrating high virological outcomes among a significant portion of Japanese people with HIV. The findings suggest that CAB+RPV maintains a favourable safety profile, with no significant effects on chronic inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.